Stocktoria
Schrodinger, Inc. SDGR
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-02-06
Schrodinger, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $255.9M | $207.5M | $216.7M | $181.0M | $137.9M |
| Gross profit | $142.6M | $132.1M | $140.7M | $101.0M | $65.6M |
| R&D expense | $173.1M | $201.8M | $181.8M | $126.4M | $90.9M |
| Operating income | -$166.9M | -$209.3M | -$177.4M | -$146.8M | -$111.4M |
| Income tax | $939,000 | $1.4M | $2.2M | $63,000 | $411,000 |
| Net income | -$103.3M | -$187.1M | $40.7M | -$149.2M | -$100.4M |
| EPS (diluted) | $-1.41 | $-2.57 | $0.54 | $-2.10 | $-1.42 |
| Operating cash flow | $13.9M | -$157.4M | -$136.7M | -$119.7M | -$70.7M |
| Free cash flow | $12.5M | -$164.7M | -$150.1M | -$127.7M | -$77.8M |
| Cash & equivalents | $230.5M | $147.3M | $155.3M | $90.5M | $120.3M |
| Total assets | $726.2M | $823.2M | $803.0M | $688.6M | $756.5M |
| Total liabilities | $362.1M | $401.8M | $254.4M | $240.7M | $199.4M |
| Shareholders' equity | $364.1M | $421.4M | $548.6M | $447.9M | $557.1M |
Source: SEC EDGAR filings · CIK 0001490978 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.